NCT03016871 2025-10-20
Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL
City of Hope Medical Center
Phase 2 Active not recruiting
Clinical Trials
16 trialsNCT07209059 2025-10-06
FINISH-HL
National Research Center for Hematology, Russia
Phase 2 Recruiting
NCT03646123 2025-08-28
Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma
Seagen Inc.
Phase 2 Terminated
NCT06812858 2025-08-19
PD-1 Inhibitors Maintenance for cHL Post-autoHCT
St. Petersburg State Pavlov Medical University
Phase 2 Recruiting
NCT03057795 2025-05-07
Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma
City of Hope Medical Center
Phase 2 Active not recruiting
NCT06931613 2025-04-17
Autologous Hematopoietic Stem Cell Transplantation in Pediatric Relapsed or Refractory Hodgkin Lymphoma After Nivolumab Treatment
St. Petersburg State Pavlov Medical University
Phase 2 Enrolling by invitation
NCT03712202 2024-11-06
Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma
City of Hope Medical Center
Phase 2 Active not recruiting
NCT03337919 2024-05-10
ANIMATE
University College, London
Phase 2 Active not recruiting
NCT03495713 2024-01-17
Lymphoma RadVax LYMPHOMA: A PHASE II TRIAL OF NIVOLUMAB + LOW DOSE RADIOTHERAPY FOR INCOMPLETE RESPONDERS
Abramson Cancer Center at Penn Medicine
Phase 2 Terminated
NCT03436862 2023-12-05
Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression Risk
SCRI Development Innovations, LLC
Phase 2 Completed
NCT02181738 2023-11-28
CheckMate 205
Bristol-Myers Squibb
Phase 2 Completed
NCT04091490 2023-09-21
Nivo-DHAP
State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia
Phase 2 Completed
NCT05772624 2023-03-16
Lowdose Nivolumab in Combination With AVD as Front Line Therapy for Classic Hodgkin's Lymphoma
Hospital Universitario Dr. Jose E. Gonzalez
Phase 2 Unknown
NCT05660993 2022-12-21
Multicenter Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab, Bendamustine, Gemcitabine, Vinorelbine (Nivo-BeGEV) in Patients With Relapsed/Refractory Hodgkin Lymphoma
National Research Center for Hematology, Russia
Phase 2 Unknown
NCT04866654 2021-08-12
RAFTING
Medical University of Gdansk
Phase 2 Recruiting
NCT03544723 2020-06-09
Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.
MultiVir, Inc.
Phase 2 Unknown